Ericka Greene, MD
Neurology · Houston, TXNPI 1720018021
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 69.0% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2019 at $29,314 and has fallen 79.1% since, to $6,121 in 2025. Among neurology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 338 payments — averaging $214.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$50K
- UCB, Inc.$6K
- Novartis$5K
- CSL Behring$5K
- Catalyst Pharmaceuticals, Inc.$2K
- AbbVie$797
- plus $3K from 31 others
Across 35 payments — averaging $6679.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$78K
- Novartis$71K
- Argenx US, Inc.$32K
- Biogen$23K
- Catalyst Pharmaceuticals, Inc.$18K
- Takeda Pharmaceuticals U.S.A., Inc.$11K
What the payments were for
- Consulting fees$19,18527%
- Speaking & faculty fees$40,69556%
- Travel & lodging$5,8138%
- Food & beverage$6,6299%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 92 | $49,928 |
| UCB, Inc. | 7 | $6,292 |
| Novartis | 21 | $5,421 |
| CSL Behring | 12 | $4,637 |
| Catalyst Pharmaceuticals, Inc. | 15 | $2,108 |
| AbbVie(2 entities) | 48 | $797 |
| Argenx US, Inc. | 11 | $555 |
| Pfizer | 14 | $290 |
| Avanir Pharmaceuticals, Inc. | 16 | $282 |
| EMD Serono, Inc. | 16 | $261 |
| Sunovion Pharmaceuticals Inc. | 10 | $184 |
| Hospira, Inc. | 9 | $176 |
| Tanabe Pharma America, Inc. | 8 | $159 |
| Biogen | 7 | $136 |
| Amgen | 6 | $136 |
| Amylyx Pharmaceuticals, Inc. | 5 | $133 |
| Grifols USA, LLC | 5 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $82 |
| Eisai Inc. | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Sanofi | 3 | $59 |
| Lilly USA, LLC | 2 | $59 |
| Johnson & Johnson(2 entities) | 3 | $54 |
| Merz North America, Inc. | 3 | $52 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| GE HealthCare | 2 | $32 |
| Saol Therapeutics Inc. | 1 | $29 |
| Boston Scientific | 1 | $23 |
| Greenwich Biosciences, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Gilead | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Genentech, Inc. | 1 | $18 |
| Strongbridge US Inc. | 1 | $17 |
| GRT US Holding, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$72,335 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 11 | $564,862 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 38 | $380,621 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 39 | $370,104 |
| Radicava OrsEdaravone | 26 | $367,080 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 50 | $242,341 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $192,811 |
| FirdapseAmifampridine Phosphate | 13 | $186,065 |
| MestinonPyridostigmine Bromide | 11 | $73,157 |
| NuedextaDextromethorphan Hbr/Quinidine | 15 | $22,378 |
| Mycophenolate Mofetil | 76 | $14,469 |
| Pyridostigmine Bromide | 90 | $7,986 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 13 | $5,144 |
| Azathioprine | 57 | $4,241 |
| Riluzole | 17 | $3,932 |
| Gabapentin | 75 | $1,598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen, Hizentra | $4,637 | $612,44589 claims |
| AstraZenecaSoliris | $49,928 | $564,86211 claims |
| Grifols USA, LLCGamunex-C | $95 | $380,62138 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $82 | $192,81113 claims |
| Catalyst Pharmaceuticals, Inc.Firdapse | $2,108 | $186,06513 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $20 | $22,455166 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $282 | $22,37815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.
Other neurology in Houston
- William OndoHouston$1.4M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Randolph EvansHouston$493K
- Leorah FreemanHouston$401K
- Mazen DimachkieHouston$388K
- Zsila SadighiHouston$361K
- Joseph JankovicHouston$323K
- Raja MehannaHouston$300K
- Eddie PattonHouston$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.